List of Excipients in Branded Drug OCUFLOX

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	OCUFLOX	ofloxacin	11980-779	BENZALKONIUM CHLORIDE
Allergan Inc	OCUFLOX	ofloxacin	11980-779	HYDROCHLORIC ACID
Allergan Inc	OCUFLOX	ofloxacin	11980-779	SODIUM CHLORIDE
Allergan Inc	OCUFLOX	ofloxacin	11980-779	SODIUM HYDROXIDE
Allergan Inc	OCUFLOX	ofloxacin	11980-779	WATER

OCUFLOX Excipient Strategy and Commercial Opportunities for Ofloxacin Ophthalmic Solution

Last updated: September 29, 2026

OCUFLOX is a sterile 0.3% ofloxacin ophthalmic solution used for bacterial eye infections. Its labeled excipient system is deliberately simple: sodium chloride, hydrochloric acid and/or sodium hydroxide for pH adjustment, and purified water. The product is an established, off-patent ophthalmic antibiotic with extensive generic competition, so commercial opportunity depends on differentiated delivery, preservative reduction, packaging, tolerability, and manufacturing efficiency rather than on the ofloxacin molecule itself.[1]

The strongest development opportunities are:

1. Preservative-free unit-dose OCUFLOX-equivalent products.
2. Low-preservative or preservative-free multidose systems.
3. Improved ocular comfort through pH, osmolality, and buffer optimization.
4. Higher-viscosity or mucoadhesive formulations that reduce dosing frequency.
5. Combination products with anti-inflammatory agents, subject to regulatory and clinical requirements.
6. Device-based differentiation, including sterile multidose dispensing systems.

What excipients are used in OCUFLOX ophthalmic solution?

The OCUFLOX label identifies the following inactive ingredients:

Component	Function
Sodium chloride	Tonicity adjustment
Hydrochloric acid and/or sodium hydroxide	pH adjustment
Purified water	Vehicle

OCUFLOX contains ofloxacin at a concentration of 0.3%, equivalent to 3 mg/mL. The formulation is an aqueous sterile solution. The label identifies a target pH range of approximately 6.0 to 6.8, which supports drug solubility and ocular tolerability.[1]

The listed formulation does not rely on a conventional antimicrobial preservative such as benzalkonium chloride. That point is commercially relevant because benzalkonium chloride exposure is associated with ocular-surface irritation, particularly in patients using topical ophthalmic medicines chronically or receiving multiple preserved products.[2]

What is the functional role of each OCUFLOX excipient?

Sodium chloride controls tonicity and helps produce an ophthalmic solution that is more compatible with the tear film. Sodium hydroxide and hydrochloric acid are processing excipients used to adjust pH. Purified water is the aqueous vehicle and must meet applicable compendial and sterile-manufacturing requirements.

The basic system has a limited excipient burden. That reduces formulation complexity, but it also leaves relatively few conventional levers for differentiation. A follow-on developer would need to create value through delivery performance, container technology, patient comfort, or a clinically meaningful dosing advantage.

How does the OCUFLOX formulation compare with generic ofloxacin ophthalmic products?

Generic ofloxacin ophthalmic solutions generally use the same active ingredient and a comparable aqueous vehicle. The principal formulation differences may involve pH adjusters, tonicity agents, buffers, viscosity modifiers, preservative systems, container-closure components, and fill volumes.

Attribute	OCUFLOX reference product	Typical generic opportunity
Active ingredient	Ofloxacin 0.3%	Ofloxacin 0.3%
Dosage form	Sterile ophthalmic solution	Sterile ophthalmic solution
Vehicle	Purified water	Purified water or equivalent compendial vehicle
Tonicity agent	Sodium chloride	Sodium chloride or alternative tonicity system
Preservative	Not identified in the cited label	May be preservative-free or use a preservative depending on product
pH control	Hydrochloric acid and/or sodium hydroxide	Comparable pH adjustment or buffered system
Differentiation	Established brand	Packaging, comfort, stability, supply, or device differentiation

A generic product does not need to copy every excipient in the reference product. Under the abbreviated new drug application pathway, the applicant must demonstrate pharmaceutical equivalence and bioequivalence, while differences in inactive ingredients must satisfy FDA safety and suitability requirements.[3]

For ophthalmic products, the absence of a conventional preservative can be a commercial advantage, but it raises sterility-maintenance and multidose-container challenges. A unit-dose package avoids repeated bottle entry but increases packaging cost, filling complexity, shipping volume, and patient handling requirements.

What formulation patents protect OCUFLOX and ofloxacin ophthalmic products?

The commercial value of OCUFLOX is no longer centered on an active-ingredient patent estate. Ofloxacin is an established fluoroquinolone, and generic manufacturers market ofloxacin ophthalmic products in the United States.

The relevant intellectual-property categories are:

• Drug-substance patents covering ofloxacin or related quinolone chemistry.
• Ophthalmic formulation patents covering solubility, pH, buffering, viscosity, or stability.
• Method-of-use patents covering treatment of specified ocular infections.
• Container-closure and dispensing-device patents.
• Manufacturing patents covering sterile filling, filtration, or crystallization.
• Combination-product patents involving ofloxacin and a corticosteroid or other ophthalmic active.

No active OCUFLOX-specific formulation patent numbers are identified in the cited FDA label materials. Product-specific patent conclusions require a current Orange Book and patent-docket review. The commercial implication is clear: a new product should be protected through a defensible formulation or device architecture rather than relying on the legacy OCUFLOX brand.

What is the Orange Book status of OCUFLOX?

OCUFLOX is associated with an FDA-approved ofloxacin ophthalmic solution reference product. Its market position is consistent with a mature, genericized product category rather than an active branded-exclusivity product.

The Orange Book analysis should distinguish:

1. The reference listed drug status of OCUFLOX.
2. Current patent and exclusivity entries associated with the reference NDA.
3. Approved generic products and their therapeutic-equivalence codes.
4. Any later-listed device, formulation, or method-of-use patents.

A developer should not assume that the absence of a current active ingredient patent eliminates all litigation risk. A later-listed formulation or device patent can create a separate Paragraph IV issue, although a simple aqueous generic generally has a lower blocking-patent exposure than a proprietary delivery system.

When did OCUFLOX lose exclusivity, and what generic entry risks exist?

OCUFLOX has been commercially exposed to generic competition for many years. The major commercial barriers are therefore regulatory execution, sterile manufacturing, product quality, distribution, and pricing rather than basic molecule exclusivity.

What would a Paragraph IV challenge involve?

A Paragraph IV certification could challenge an Orange Book-listed patent on grounds that the patent is invalid, unenforceable, or not infringed. For a conventional ofloxacin ophthalmic solution, likely litigation targets would include:

• Formulation claims.
• Stability claims.
• Container or dispensing-device claims.
• Method-of-use claims.

The commercial importance of a Paragraph IV challenge depends on whether the targeted patent covers the reference product itself, a specific indication, a formulation feature, or a delivery device. A generic applicant may design around device or formulation claims while retaining the same active ingredient and concentration.

A plain 0.3% aqueous solution has limited patent differentiation. A preserved multidose product, preservative-free multidose product, gel-forming solution, or combination product may create a stronger patent position but also increases development and regulatory complexity.

What excipient strategies offer the best commercial opportunity?

Preservative-free unit-dose OCUFLOX-equivalent

A unit-dose product can target patients with ocular-surface sensitivity, postoperative use, pediatric administration, or concurrent treatment with multiple eye drops. The commercial case depends on manufacturing cost and channel demand.

Potential advantages include:

• No repeated exposure to a bottle preservative.
• Reduced risk of in-use microbial contamination.
• Better positioning for ocular-surface tolerability.
• Compatibility with hospitals, ambulatory surgery centers, and specialty ophthalmology.

The main disadvantages are higher packaging cost, more waste, and less convenient use for patients requiring frequent dosing.

Preservative-free multidose delivery

Preservative-free multidose systems use one-way valves, sterile air filtration, collapsible containers, or other designs that prevent microbial ingress. This approach can combine the convenience of a bottle with lower preservative exposure.

The device may provide stronger patent potential than a simple excipient change. Protection can cover the container, valve, venting system, dose-metering mechanism, or aseptic filling process. Regulatory review must address extractables, leachables, dose uniformity, container integrity, microbial ingress, and in-use stability.

Viscosity-enhanced formulations

Hydroxypropyl methylcellulose, hydroxypropyl cellulose, povidone, carbomers, hyaluronic acid, and related polymers can increase residence time on the ocular surface. A higher-viscosity system may reduce drainage and improve exposure, although it can also cause blurred vision, stinging, altered drop size, or manufacturing challenges.

For ofloxacin, a viscosity-enhanced formulation could support claims related to dosing convenience or residence time. Those claims would require appropriate clinical evidence and would not arise automatically from adding a polymer.

Buffer and comfort optimization

The OCUFLOX formulation uses pH adjustment without a complex buffer system identified in the label. A developer could evaluate citrate, phosphate, borate, or other ophthalmic buffer systems, but the benefit must be balanced against ocular tolerability and compatibility with the active ingredient.

Relevant development endpoints include:

• Initial comfort and stinging.
• Tear-film recovery.
• Ocular-surface staining.
• Drop pH and osmolality.
• Chemical stability.
• Preservative efficacy where applicable.
• Compatibility with the container-closure system.

A lower-irritation formulation may support commercial differentiation, but comfort claims require controlled comparative studies.

Combination products

Ofloxacin could be combined with a corticosteroid for postoperative inflammation or infection-risk management. Combination products have greater commercial potential than an undifferentiated ofloxacin generic, but they face higher clinical, regulatory, and patent barriers.

Development risks include:

• Separate dose-response requirements for each active.
• Sterility and stability of both actives.
• Increased concern about antimicrobial resistance and steroid-related adverse effects.
• Potentially stronger competitor estates.
• Need for clinical evidence supporting the combination.

The combination category is commercially attractive only where the product solves a defined treatment problem and can secure reimbursement or physician adoption.

What FDA regulatory pathway applies to an OCUFLOX follow-on product?

A conventional ofloxacin ophthalmic solution would generally be developed through an ANDA if it is pharmaceutically equivalent to the reference listed drug. The applicant must address active ingredient identity, strength, dosage form, route of administration, quality, sterility, inactive ingredients, and bioequivalence requirements.[3]

A materially different product may require a 505(b)(2) application. That pathway may be relevant to:

• A new viscosity-enhanced formulation.
• A novel multidose preservative-free device.
• A new concentration.
• A combination product.
• A formulation with a different dosing regimen or clinical indication.

The pathway affects development cost, clinical requirements, labeling flexibility, and the ability to obtain new regulatory exclusivity.

How strong is the OCUFLOX patent estate?

The legacy OCUFLOX estate is commercially weak as a barrier to ordinary generic entry because the product is mature and the active ingredient is widely genericized. The stronger protection opportunities are prospective rather than historical.

Strategy	Patent strength	Regulatory burden	Commercial differentiation
Simple 0.3% aqueous generic	Low	Low to moderate	Low
Preservative-free unit dose	Moderate	Moderate	Moderate
Preservative-free multidose device	High if technically novel	High	High
Viscosity-enhanced solution	Moderate	Moderate to high	Moderate
Ofloxacin-corticosteroid combination	Moderate to high	High	High
Novel delivery device	High if validated and non-obvious	High	High

Patent claims should focus on measurable technical features: microbial ingress performance, preservative-free in-use stability, dose uniformity, viscosity range, particle-size control, pH and osmolality window, container materials, or manufacturing controls. Broad claims covering only "ofloxacin in an ophthalmic solution" are likely to face validity and prior-art pressure.

Which companies are challenging OCUFLOX commercially?

The competitive field includes generic manufacturers of ofloxacin ophthalmic solution and branded or generic alternatives containing other fluoroquinolones, including ciprofloxacin, moxifloxacin, and gatifloxacin where approved and commercially available.

Competitive pressure comes from:

• Low-cost ofloxacin generics.
• Newer fluoroquinolone formulations.
• Preservative-free antibiotic products.
• Combination antibiotic-steroid drops.
• Hospital and ambulatory-care purchasing contracts.
• Private-label and wholesaler products.

The main commercial risk is price erosion. A standard generic product requires low-cost sterile ophthalmic manufacturing and reliable supply. A differentiated product can protect margins, but its price premium must be supported by convenience, tolerability, packaging, or clinical utility.

What manufacturing and geographic barriers affect commercialization?

Ophthalmic solutions require validated sterile manufacturing, aseptic filling or terminal sterilization where appropriate, container-closure integrity testing, particulate control, and rigorous microbiological quality systems. Manufacturing barriers include:

• Sterile filtration and aseptic processing validation.
• Compatibility between ofloxacin and the container.
• Low extractables and leachables.
• Consistent fill volume and drop size.
• Stability under temperature and light stress.
• In-use microbial protection.
• Supply of sterile unit-dose containers or specialized multidose devices.

Geographic expansion also requires country-specific registration, pharmacopoeial compliance, labeling, and device qualification. The United States, European Union, Japan, and emerging markets may differ in allowable excipients, preservative expectations, packaging standards, and generic-substitution rules.

What is the commercial outlook for OCUFLOX excipient innovation?

The highest-value opportunity is not another undifferentiated ofloxacin solution. It is a preservative-free or low-irritation product supported by a reliable delivery system and a defensible patent position.

A commercially credible product profile would include:

• Ofloxacin 0.3%.
• Preservative-free multidose or unit-dose delivery.
• Demonstrated sterility throughout labeled use.
• Acceptable pH and osmolality.
• Low ocular discomfort.
• Stable potency and impurity profile.
• Reproducible drop size.
• Packaging suitable for pharmacy, hospital, and surgical channels.
• Patent claims directed to the formulation-device combination.

Revenue exposure for a standard generic would be limited by price competition and substitution. A specialty or device-enabled product could support higher margins, but it would require clinical, regulatory, and manufacturing investment that exceeds the requirements for a conventional ANDA.

Key Takeaways

• OCUFLOX is a 0.3% ofloxacin sterile ophthalmic solution with sodium chloride, pH adjusters, and purified water listed as inactive ingredients.
• The product is a mature, genericized antibiotic with limited legacy exclusivity value.
• The most attractive excipient strategy is preservative-free delivery, especially through unit-dose or multidose sterile dispensing systems.
• Viscosity enhancement and comfort-focused pH or osmolality optimization offer secondary differentiation routes.
• A conventional aqueous generic is likely to face substantial price competition.
• The strongest prospective patents are likely to cover container technology, microbial protection, formulation ranges, stability, and manufacturing processes.
• Combination products may offer greater commercial value but carry materially higher clinical and regulatory risk.
• Biosimilar risk does not apply because OCUFLOX is a small-molecule ophthalmic drug, not a biologic.
• A conventional generic would generally fit the ANDA pathway, while materially differentiated products may require a 505(b)(2) application.

FAQs About OCUFLOX Excipient and Commercial Strategy

Is OCUFLOX preservative-free?

The cited OCUFLOX label lists sodium chloride, hydrochloric acid and/or sodium hydroxide, and purified water as inactive ingredients and does not identify a conventional antimicrobial preservative.[1]

Can sodium chloride be replaced in an ofloxacin ophthalmic formulation?

Yes, another tonicity-adjustment system may be possible, but the replacement must satisfy safety, stability, compatibility, and regulatory requirements for ophthalmic use.

Can a generic manufacturer use different excipients from OCUFLOX?

Yes. An ANDA applicant may use different inactive ingredients if the formulation meets applicable FDA safety, suitability, pharmaceutical-equivalence, and bioequivalence requirements.[3]

Does OCUFLOX have biosimilar competition?

No. Biosimilar regulation applies to biological products. Ofloxacin ophthalmic solution is a small-molecule drug and competes through generic drug pathways.

What is the best patent strategy for a new OCUFLOX-equivalent product?

The strongest strategy is usually a formulation-device combination covering preservative-free multidose performance, microbial ingress control, dose uniformity, stability, and validated manufacturing parameters.

References

1. U.S. Food and Drug Administration. (n.d.). OCUFLOX (ofloxacin ophthalmic solution) prescribing information. FDA labeling database.
2. Baudouin, C., Labbé, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010). Preservatives in eye drops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312-334.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Content and format. FDA guidance and regulatory requirements.